GLP1R and hydrops fetalis: First, their conclusion that GLP-1 agonists were associated with lower risks of HF hospitalization appear to have been driven largely by direct evidence which included only 9 total HF hospitalization events from 5 trials, resulting in a HR of 3.23 (comparing DPP-4 inhibitors to GLP-1 agonists) with very wide confidence intervals (0.70, 24.70).